Clinical Trial Update: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory diffuse large B-cell lymphoma has completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Status: COMPLETED | Results posted: 2024-03-07